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Abstract: Alternatively-activated pathways have been observed in biological experiments in cancer
studies, but the concept had not been fully explored in computational cancer system biology. Therefore,
an alternatively-activated pathway identification method was proposed and applied to primary
breast cancer and breast cancer liver metastasis research using microarray data. Interestingly, the
results show that cytokine-cytokine receptor interaction and calcium signaling were significantly enriched
under both conditions. TGF beta signaling was found to be the hub in network topology analysis.
In total, three types of alternatively-activated pathways were recognized. In the cytokine-cytokine
receptor interaction pathway, four active alteration patterns in gene pairs were noticed. Thirteen
cytokine-cytokine receptor pairs with inverse activity changes of both genes were verified by the
literature. The second type was that some sub-pathways were active under only one condition.
For the third type, nodes were significantly active in both conditions, but with different active genes.
In the calcium signaling and TGF beta signaling pathways, node E2F5 and E2F4 were significantly active
in primary breast cancer and metastasis, respectively. Overall, our study demonstrated the first time
using microarray data to identify alternatively-activated pathways in breast cancer liver metastasis.
The results showed that the proposed method was valid and effective, which could be helpful for
future research for understanding the mechanism of breast cancer metastasis.
Keywords: alternatively-activated pathway; breast cancer; liver metastasis; microarray; gene
active status
1. Introduction
Cancer is a leading cause of death in the world. Breast cancer is the leading cause of cancer-related
death among females worldwide. In 2012, an estimated 1.7 million cases and 521,900 deaths occurred [1].
Cancer lethality is mainly caused by metastasis, accounting for over 90% of human cancer deaths [2].
Despite its clinical importance, little is known about the genetic and biochemical determinants
of metastasis.
Understanding the nature of the genes involved in metastasis has been an important goal for the
past several decades. Along with the development of microarray and other high-throughput sequencing
technologies, plenty of new prognostic markers (metastasis signatures or differentially-expressed
genes) that predict metastasis risk in patients with breast cancer were reported [3]. A set of 70 genes
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(MammaPrint DX) was identified to predict the likelihood of distant metastases in young patients
in a retrospective study [4]. The 70-gene signature was validated in several independent studies,
such as Van de Vijver [5], Bueno-de-Mesquita et al. [6], Buyse et al. [7], Mook et al. [8,9], Wittner
et al. [10], and Curtis [11]. Another 76-gene signature was retrospectively reported to be able to predict
the outcome in patients of all age groups with lymph-node-negative breast cancer using a different
microarray platform [12]. In these studies, the gene signatures were proven to be more powerful
than traditional clinical parameters (the St Gallen criteria [13] and the National Institutes of Health
criteria [14]). In addition, many other studies also reported metastasis gene signatures, including Ma
et al. [15] (2 genes), Pail et al. [16] (21 genes), Landemaine et al. [17] (6 genes), and Patsialou et al. [18]
(Human Invasion Signiture, HIS, 445 transcripts, of which 185 were annotated protein-genes). While
these prognostic markers, i.e., signatures, are extremely valuable in predicting breast cancer metastasis,
they were not studied for identifying drug targets or developing new treatment strategies for metastatic
breast cancer.
In this paper, we used microarray data collected from public domain resources and studied the
similarities and differences of molecular pathways between breast cancer primary tumor and breast
cancer liver metastasis samples. Biological changes that occur during the metastatic progression of
breast cancer are still incompletely characterized [19]. Pathway analysis strategies have been widely
used in cancer research and identified some metastasis-related pathways, such as in breast cancer [20–22],
pancreatic ductal adenocarcinoma [23], and colorectal cancer [24,25]. In this study, we are not only
interested in the molecular pathways that are enriched in the breast cancer liver metastasis tumors,
but also the alternatively-activated pathways when the breast cancer primary tumors metastasize to the
liver. The alternatively-activated pathway is defined as the activated pathway in different states, such
as primary tumors vs. metastasis tumors, tumors with or without treatment. In those conditions, there
are different differentially-expressed/-enriched genes, or different pathway/sub-pathway topologies,
or different active sub-pathways. Many alternatively-activated/rewired pathways in cancers via
biological experiments were detected, such as the cell polarity signaling pathway [26], apoptotic
signaling networks in anticancer drugs enhances cell death research [27], and alternatively-activated
ERK-JNK signaling pathways in melanoma [28]. The time course was used mechanistically to
detect alternatively-activated pathways (dynamical system models) under each condition in the
Q-method [29]. However, this alternatively-activated pathway concept has not been fully explored
using the computational cancer system biology method.
Common approaches to identify pathways or gene expression signatures or any other list of
differentially-expressed genes include individual gene analysis (IGA) and gene set analysis (GSA) [30,31].
Both methods are used to investigate whether the identified gene signatures are statistically enriched
with genes from predefined pathways. In IGA techniques, such as the Database for Annotation,
Visualization and Integrated Discovery (DAVID) [32,33], there are mainly two steps. The first step
is to identify significantly differentially-expressed genes (DEGs) either between different groups or
conditions such as between a primary cancer group and a metastatic group. The over-representation of
these DEGs in specific pathways is then determined by counting statistics, such as Fisher’s exact test or
Chi squared analysis. In contrast, GSA techniques, such as Gene Set Enrichment Analysis (GSEA) [34],
take all genes in a predefined pathway and calculate a gene-level statistic for each gene. Next, a
pathway-level statistic is derived by combining the gene-level statistics, and to determine whether the
pathway represented by the gene set is significantly perturbed. Other pathway analyses integrated
the topology of signaling pathways into their enrichment analyses [35,36]. However, none of these
existing pathway analyses can be directly applied to identify our hypothesized alternatively-activated
pathways that happen when the breast cancer primary tumors metastasize to the liver.
Although a number of breast cancer metastasis pathways were identified [37,38], their regulatory
mechanisms and differences between primary tumor and metastatic tumor have not been described.
Understanding the altered regulatory mechanisms can aid us in understanding and eventually treating
metastatic breast cancer.
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In this paper, we developed a novel pathway enrichment analysis method that can identify
differentially-enriched pathways between two conditions using microarray data. Notably, it can identify
alternatively-activated pathways when primary tumors metastasize to distal sites. To demonstrate
its application, breast cancer liver metastasis tumors were used to investigate the uniquely enriched
pathways and alternatively-activated pathways compare to primary tumors.
2. Materials and Methods
The microarray data for primary breast cancer and metastasis were downloaded from the Gene
Expression Omnibus (GEO) database, and genes were first classified as active or inactive based on
present/margin/absent (PMA) information. Next, the alternatively-activated gene pathways were
calculated based on the proposed method. Finally, the pathway networks were used to better
understand the identified alternatively-activated pathways, and the 3 top selected different types of
alternatively-activated pathways were further analyzed.
2.1. Gene Expression and Pathways
The gene expression microarray data were download from the GEO database. One hundred fifty
three samples were in the primary breast cancer group [39] (GSE65194, Affymetrix Human Genome
U133 Plus 2.0 Array), and 43 samples were in the breast cancer metastasized to liver group [40,41]
(GSE46141: 16 samples, and GSE56493: 27 samples, Rosetta/Merck Human RSTA Custom Affymetrix
2.0 microarray). GSE65194 contains 130 breast cancer samples (41 TNBC; 30 Her2; 30 Luminal B and 29
Luminal A) and 23 technical duplicates. As there was a sample imbalance between the primary cancer
group and metastatic cancer group, we performed a bootstrap analysis. Each time, 43 samples were
randomly selected from the primary cancer group and compared to the 43 samples from the metastatic
cancer group. Pathway analysis was then performed based on the DEGs. We repeated this 10 times.
A total of 186 KEGG pathways and 676 REACTOME pathways were downloaded from MsigDB
v6.0 [34] and used for the pathway analysis.
2.2. Gene Expression Data Pretreatment
The R package “affy” was used to analyze the retrieved CEL files containing the raw microarray
data. We calculated the PMA information (present/margin/absent) for each probe and transformed
it to the gene expression status. A probe with P (present) status means that this probe is active in
this sample and will be kept for further analysis. If any probe for a gene was active, the gene was
considered as active. Genes without an active probe were considered inactive.
2.3. Breast Cancer Liver Metastasis Uniquely-Enriched Pathway Analysis
To determine alternatively-activated pathways in liver metastasis, we used an IGA-like two-step
method. In Step 1, we identified the differentially-expressed active genes; and in Step 2, we identified
the differentially-activated pathways (Figure 1).
Step 1: For each gene, we calculated the number of active samples in the primary cancer group
(denoted as n11), the number of inactive samples in the primary cancer group (denoted as n12), the
number of active samples in the metastatic cancer group (denoted as n21), and the number of inactive
samples in the metastatic cancer group (denoted as n22). Both the left and right one-tailed Fisher’s exact
tests were performed. To test whether a gene was more active in primary cancer than in metastatic
cancer (left one-tailed test), the hypothesis is:
H0: p1 = p2 H1: p1 > p2 (1)
To test whether a gene was more active in metastatic cancer than in primary cancer (right one-tailed
test), the hypothesis is:
H0: p1 = p2 H1: p1 < p2 (2)
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where p1 is the proportion of active samples in primary cancer (n11/(n11+n12)) and p2 is the proportion
of active samples in metastatic cancer (n21/(n21+n22)).Genes 2019, 10, 753 4 of 19 
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pathway was more active in primary cancer than in metastatic cancer or more active in metastatic 
cancer than primary cancer, or not significantly different between primary cancer and metastatic 
cancer. Suppose the numbers of primary-cancer-active genes, metastatic-cancer-active genes, and 
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i re 1. .
After these 2 tests with a threshold p < 0.05, the genes were divided into 3 sets: primary-cancer-
active, metastatic-cancer-active, and no significa t differential activity between primary cancer
and metastatic cancer. I the proposed method, these significant primary-cancer-active and
metastatic-cancer-active genes were consi ered as differentially-activated genes.
Step 2: for each pathway, two one-tailed Fisher’s exact tests were performed to test whether this
pathway was more active in primary cancer than in metastatic cancer or more active in metastatic
cancer than primary cancer, or not significantly different between primary cancer and metastatic cancer.
Suppose the numbers of primary-cancer-active genes, metastatic-cancer-active genes, and total genes
in a pathway ar mp, mm, m and the numbers of primary-cancer-ac ive genes, etast ti -cancer-active,
a d total genes are Np, Nm, N. The hypothesis in the first one-tailed Fisher’s exact test is:
H0: p3 = p4 H1: p3 > p4 (3)
where p3 is the proportion of primary-cancer-active genes in this pathway (
mp
m ) and p4 is the proportion
of primary-cancer-active genes out of this pathway (
Np−mp
N−m ).
The hypothesis in the second one-tailed Fisher’s exact test s:
H0: p5 = p6 H1: p5 > p6 (4)
where p5 is the proportion of metastatic-cancer-active genes in this pathway (
mm
m ) and p6 is the
proportion of metastasis-cancer-active genes out of this pathway (Nm−mmN−m ).
We used p < 0.05 as the significance threshold for both tests.
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2.4. Gene-Gene Activity Alteration Patterns’ Recognition
Even in a significant metastasis-related pathway, not all the gene-gene regulations are changed.
For each gene-gene pair, there are different activity alteration patterns between primary cancer and
metastatic cancer. We defined 4 types of activity alterations as follows. The cytokine-cytokine receptor
relationships are shown as an example in Figure 2.
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2.5. Bayesian Network Construction
Several networks and network-based approaches have been widely used in cancer research, such
as human interactome data [42] and gene co-expressed protein interaction networks [43]. In the human
interactome, although some gene interactions can be directed, most of them are used as an undirected
network in the current network-based methods. A Bayesian network is a probabilistic network that
takes a group of random variables and their conditional dependencies to represent them as a directed
acyclic graph (DAG). To identify a network structure that best interprets the input, we used the “greedy
equivalence search” (GES) method, a score-based algorithm that generates a pattern that represents
the optimal causal network [44]. With the assumption that the true regulatory network is a DAG,
the greedy search algorithm sequentially applies two phases: a “forward phase” and a “backward
phase”, where the “forward phase” provides a pattern that includes the optimal network, while the
“backward phase” returns a pattern that is equivalent to the optimal network. The algorithm will
terminate when no more edges can be added to or removed from the graph. In this study, we used
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the fast greedy search (FGS) algorithm [45], which is an optimized and parallelized implementation
of GES. FGS was used to build a directed gene network (DGN) for primary breast cancer and breast
to liver metastasis data. FGS algorithm is mainly controlled by two parameters that can affect the
density of the network: penalty discount and depth. The penalty discount is the BIC score that FGS
uses to evaluate networks. Depth refers to the degree constraint of each node. We chose a low penalty
discount score and unlimited degree constraint (PD = 6, depth = −1) to allow high degree nodes.
2.6. Expand Pathways with the Bayesian Network
Bayesian networks may provide novel relationships among genes, not available in the pathway
databases. They are directed networks that are different from the protein interaction networks or gene
co-expressed networks. We could get the upstream or downstream gene information from the Bayesian
network, even though these gene relationships may be potentially regulated. We expanded each
pathway using the downstream genes in the Bayesian networks. The expanded primary/metastatic
cancer pathways should have a higher probability to be active in the primary/metastatic cancer situation
and more possible with specific biological meanings.
We expanded each pathway with two Bayesian networks constructed from primary breast cancer
data and breast to liver metastatic cancer data separately (Figure 3). For gene I in a pathway, if gene J
regulates I or is regulated by I in the Bayesian network, gene J will be added into this pathway. After
we expanded all the genes in each pathway using Bayesian networks, we got two new pathway gene
sets. We repeated this procedure 3 times, and finally, we obtained 7 pathway gene sets (1 raw pathway
gene set, 3 expanded pathway gene sets with the primary cancer Bayesian network, and 3 expanded
pathway gene sets with the metastatic cancer Bayesian network).
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2.7. Connectivity among Pathways: Pathway Networks
To further explore the connectivities among pathways, we constructed a pathway network based
on Fisher’s exact tests (hypergeometric distribution test) between pathways. Suppose there are nall
genes in all the pathways, na genes in Pathway A, nb genes in Pathway B, and nab genes in both
Pathways A and B; the p-value of this test is calculated by:
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p = 1−
∑nab−1
i=1
CinaC
nb−i
nall−na
Cnbnall
(5)
After calculating the p-value, we performed multiple tests’ adjustment using the FDR method in
R (“fdr” in the “p.adjust” function) [46]. An FDR <0.05 was chosen as the threshold. After the test, we
retained all the significant pairs between differentially-active pathways and constructed the pathway
network using Cytoscape [47]. We only constructed the pathway network for KEGG pathways. First,
we constructed pathway networks using genes in each pathway from the database, and we called it the
general condition. Next, we constructed pathway networks based on genes in extended pathways, and
we called it the primary breast cancer or breast cancer liver metastasis condition. Lastly, we compared
these networks and determined primary breast cancer-specific pathway connections and breast to liver
metastatic specific pathway connections.
3. Results
3.1. Raw Pathway Analysis
Out of the 186 KEGG pathways, 17 pathways were significantly enriched among primary breast
cancer active genes, and 24 pathways were significantly enriched among breast cancer liver metastasis
active genes. Interestingly, two pathways, cytokine-cytokine receptor interaction (hsa04060) and calcium
signaling (hsa04020), were significantly enriched under both conditions. The p-values and statistics of
these 186 pathways are in Supplemental Table S1.
Out of the 676 REACTOME pathways, 39 pathways were significantly enriched among primary
breast cancer active genes, and 81 pathways were significantly enriched among breast cancer liver
metastasis active genes. Two pathways, chemokine receptors bind chemokines (R-HSA-380108) and peptide
ligand-binding receptors (R-HSA-375276), were significantly enriched under both conditions. Chemokine
receptors bind chemokines is a subset of peptide ligand-binding receptors.
Chemokine receptors are cytokine receptors found on the surface of certain cells, which interact
with a type of cytokine called chemokines. This REACTOME pathway, chemokine receptors bind chemokines
R-HAS-380108, is highly related to the KEGG pathway cytokine-cytokine receptor interaction has04060.
Therefore, we further analyzed the cytokine-cytokine receptor interaction pathway in the next step.
3.2. Robustness Analysis
As there were about 3.5-times more samples in the primary cancer group than the metastatic
cancer group, we performed robustness analysis for the group imbalance. We randomly selected
43 samples from the primary cancer group and performed pathway analysis with the 43 metastatic
cancer samples. This procedure was repeated 10 times.
First, we compared the active genes between the primary and metastatic samples. Of these,
1481/4523 primary/metastatic cancer active genes were identified based on all 153/43 samples, and on
average, 1163.4/3895.6 primary/metastatic cancer active genes were found using the random balanced
43/43 samples. We obtained 78%/86% active genes using random samples compared to using all
the samples, and most of the active genes (number: 1131.1/3839.9, proportion: 97.41%/98.58%) in
the random analysis can be found from the analysis using all samples. The detailed results are in
Supplemental Table S2.
After obtaining the active genes, we compared the KEGG pathways. The 17/23 primary/metastatic
cancer active pathways were found using all 153/43 samples, and on average, 11.9/23.3 primary/
metastatic cancer active pathways were identified using the random 43/43 samples. Most of the active
pathways (number: 10.6/21.3, proportion: 89.38%/91.44%) in the random analysis were the same
from the analysis using all the samples. The results using different data were highly correlated, with
an average Pearson correlation coefficient of 0.9035 and 0.9633 for primary cancer active pathways
and metastatic cancer pathways, respectively. The pathways cytokine-cytokine receptor interaction and
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calcium signaling can be found in most of the results from random samples. The detailed results are in
Supplemental Table S3.
Through the active gene and pathway robustness analysis for group imbalance, the proposed
method was robust for the sample size imbalance.
3.3. Expanded Network
After expanding the pathways with Bayesian networks, the numbers of genes in each pathway
increased exponentially (Supplemental Figure S1). The number of significantly differentially-active
pathways was also greatly increased (Table 1). Basically, the primary cancer Bayesian network
contained more information about genes active in primary cancer, and the metastatic cancer Bayesian
network contained more information about genes active in metastatic cancer. Therefore, we obtained
more significant primary-active pathways in primary-expanded networks and more metastasis-active
pathways in metastasis-expanded networks. From Table 1, we can see that the more steps we expanded,
the more significant results we obtained. After two or more steps, the influence of the Bayesian
network was much greater than the raw pathway. Because of this, we only used the results in a
one-step expansion.
Table 1. Number of significant KEGG pathways using different pathway resources.
Pathway Resource Number of Significant PrimaryCancer-Related Pathways
Number of Significant Metastatic
Cancer-Related Pathways
Raw pathways 17 24
Expanded pathways by primary
cancer Bayesian network 1 time 22 13
Expanded pathways by primary
cancer Bayesian network 2 times 41 0
Expanded pathways by primary
cancer Bayesian network 3 time 55 0
Expanded pathways by metastatic
cancer Bayesian network 1 time 11 34
Expanded pathways by metastatic
cancer Bayesian network 2 times 5 49
Expanded pathways by metastatic
cancer Bayesian network 3 time 1 48
3.4. Pathway Network
We found 109 pathway connections among 35 significant differentially-active pathways in the
general condition without considering any disease status (Figure 4). Among these pathway connections,
86 pathway connections among 16 significant differentially-active pathways were in primary breast
cancer (Supplemental Figure S2), and 96 pathway connections among 24 significant differentially-active
pathways were in breast cancer liver metastasis (Supplemental Figure S3). The connections in the
primary breast cancer or breast cancer liver metastasis were calculated based on the extended pathways
separately. One hundred twelve pathway connections among 35 significant differential pathways were
found to be in the cancer condition (primary cancer + metastatic cancer; Supplemental Figure S4).
As seen from these figures, there were two major clusters in the network. Primary cancer-related
pathways were more likely connected with each other, while metastatic cancer-related pathways were
more likely to connect with each other. The primary cancer-related pathways were frequently related
to the immune system. The metastatic cancer-related pathways were frequently related to metabolism,
such as linoleic acid metabolism.
After comparing 86 pathway connections between the primary breast cancer and 96 pathway
connections in the breast cancer liver metastasis, we found 70 common pathway connections. Next,
we analyzed the 16 primary breast cancer-specific pathway connections (Supplemental Figure
S5) and 26 breast cancer liver metastasis-specific pathway connections (Supplemental Figure S6).
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In Supplemental Figure S5, we find two hub pathways for primary breast cancer: hematopoietic cell
lineage and cell adhesion molecules cams. In Supplemental Figure S6, we found a significant metabolism
pathway clique and a hub pathway for the breast cancer liver metastasis: TGF beta signaling.
After comparing the pathway connections between the general condition and cancer condition,
we found 103 common connections and nine cancer-specific connections (Supplemental Figure S7).
Again, TGF beta signaling was found to be a hub pathway.
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3.5. Alternatively-Activated Pathways
After getting the metastasis-related pathways, one important task was to explore the function
of these pathways. In different conditions, such as primary cancer vs. metastatic cancer, the gene
regulation patterns or topologies in pathways were different, and we refer to these active sub-pathways
in this research as differentially-activated pathways.
Taking the three significant metastasis-related pathways as an example, we recognized three
distinctive types of alternatively-activated pathways. These three pathways were the cytokine-cytokine
receptor interaction, calcium signaling pathway, and TGF beta signaling pathways.
In the cytokine-cytokine receptor interaction pathway, there was only one edge between each
cytokine-cytokine receptor pair (Figure 5a). For each cytokine-cytokine receptor pair, the test results of
gene-gene active alteration patterns are shown in Supplemental Table S4. For each gene-gene pair,
there may be several significant active alteration patterns. We selected the pattern with the minimal
p-value as its regulatory alteration pattern because the pattern with the minimal p-value should be
the most possible pattern. Taking IL20-IL20RA (IL-10 family) as an example, patterns 00→10, 00→11,
01→10, 01→11 were all significant, but pattern 01→10 had the minimal p-value (0.00015), so we set
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this gene pair with the inverse pattern (both genes’ activity changes inversely). As a result, we found
four gene-gene pairs with 01→10 patterns and nine gene-gene pairs with 10→01 patterns (Figure 5b).Genes 2019, 10, 753 10 of 19 
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The functions of these 13 cytokine-cytokine receptor pairs were further verified (Table 2). The results
show that most of the cytokines or cytokine receptors (except IL12 and IL12RB1) were related to breast
cancer or metastasis. This nicely verified our method for mining metastasis-related pathways and
regulation pairs.
The second pattern of pathway regulation was that some sub-pathways in a pathway were
active under one condition (primary breast cancer or breast cancer liver metastasis), but not in both.
Identifying these alternatively-activated sub-pathways in the breast cancer liver metastases was our
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best interest. For example, in the calcium signaling pathway (Figure 6), we found that the sub-pathway
TnC, PHK, CAMK, NOS, ADCY, FAK2, IP3-3K was only active in breast cancer liver metastasis.
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The third pattern of pathway regulation is that nodes were significantly active in both primary
breast cancer and breast cancer liver metastasis, but the active genes in these nodes were different.
Node CALM in calcium signaling represented any of these seven genes: CALM1, CALM2, CALM3,
CALML3, CALML4, CALML5, and CALML6. We found that CALM2 and CALML5 were significantly
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active in primary breast cancer, while CALML3 and CALML6 were significantly active in breast cancer
liver metastasis. Node BMP contained 11 different genes (GDF5, GDF6, GDF7, AMH, BMP2, BMP4,
BMP5, BMP6, BMP7, BMP8A, BMP8B). BMP8B was significantly active in primary breast cancer, while
BMP2, BMP4, BMP5, BMP6, BMP8B were significantly active in liver metastasis. Node E2F4/5 can
be E2F4 or E2F5. E2F5 was significantly active in primary breast cancer, and E2F4 was significantly
active in the metastasis. Therefore, a pathway may be active in both primary cancer and metastatic
cancer, but their mechanisms could be different. In TGF beta signaling pathway (Figure 7), taking the
sub-pathway from TGFB to E2F4/5 as an example, in primary breast cancer, gene DCN (node Decorin)
was active, and it inhibited TGFB expression; however, RBL1 (node p107) and E2F5 were active (active
sub-pathway DCN-TGFB-RBL1-E2F5); in breast to liver metastatic cancer, TGFB3 (node TGBF) was
active, as well as E2F4 (active sub-pathway TGFB3-E2F4).
Table 2. Literature verification for the 13 cytokine-cytokine receptor pairs.
Type Cytokine CytokineReceptor Pattern Function
Chemokines
CXCL11 CXCR3 10→01 CXCR3 is a molecular target in breast cancer metastasis [48,49]
CXCL13 BLR1 10→01 CXCL13 is overexpressed in breast cancer patients [50,51]
CCL2 CCR2 10→01
the CCL2-triggered chemokine cascade in macrophages
promotes metastatic seeding of breast cancer cells, thereby
amplifying the pathology already extant in the system [52]
CCL2/CCR2 chemokine signaling coordinates the survival and
motility of breast cancer cells with implications on the
metastatic process [53]
PDG family VEGFC FLT4 10→01
activation of the VEGF-C/Flt-4 axis enhances mobility of cancer
cells and contributes to the promotion of metastasis in animals
[54] VEGF-C-VEGFR3/Flt4 axis regulates mammary tumor
growth and metastasis in an autocrine manner [55] VEGF-C/D
and Flt-4 may play an important role in the process of lymphatic
metastasis of early-stage invasive cervical carcinoma through
paracrine and autocrine mechanisms [56]
FLT3LG FLT3 10→01 FLT3-ligand administration inhibits liver metastases [57]
TNF family TNFSF8 TNFRSF8 10→01 TNF inhibitor suppresses bone metastasis in a breast cancer cellline [58]
IL-1 family IL1B IL1R2 10→01
IL-1B is a potential biomarker for predicting breast cancer
patients at increased risk for developing bone metastasis [59]
IL-1 drives breast cancer growth and bone metastasis in vivo
[60]
IL-10 family
IL20 IL20RA 01→10
IL-20 plays pivotal roles in the tumor progression of breast
cancer; IL-20 may be a novel target in treating breast
tumor-induced osteolysis [61]
IL22 IL22RA2 01→10 IL-22 promotes epithelial cell transformation and breasttumorigenesis [62]
TGF-b family
BMP2
BMPR1B 01→10
Bone morphogenic proteins are related to driving breast cancer
metastasis to bone [63] The BMP2/7 heterodimer inhibits the
human breast cancer stem cell subpopulation and bone
metastases’ formation [64] TGF-β activity is controlled by the
expression of BMP7; BMP7 expression has been shown to be
inversely proportional to the tumorigenicity and invasive
behavior of MDA-MB-231 breast cancer cells [65] The presence
of high levels of BMP7 expression in primary tumors has been
strongly associated with accelerated bone metastasis, especially
from ductal carcinomas [66]
BMP7
Hematopoietic IL12A IL12RB1
10→01
NA
IL12B 10→01
Genes 2019, 10, 753 13 of 19
Genes 2019, 10, 753 12 of 19 
 
 
Figure 7. Gene activities in the TGF beta signaling pathway. 
3.5. Alternatively-Activated Pathways 
After getting the metastasis-related pathways, one important task was to explore the function of 
these pathways. In different conditions, such as primary cancer vs. metastatic cancer, the gene 
regulation patterns or topologies in pathways were different, and we refer to these active sub-
pathways in this research as differentially-activated pathways.  
Taking the three significant metastasis-related pathways as an example, we recognized three 
distinctive types of alternatively-activated pathways. These three pathways were the cytokine-cytokine 
receptor interaction, calcium signaling pathway, and TGF beta signaling pathways.  
Figure 7. Gene activities in the TGF beta signaling path ay.
4. Discussions
Instead of gene expression data, we used PMA information for each gene and divided genes
into the active set and inactive set. Using an IGA-like strategy and integrating information from
Bayesian networks, we identified several metastasis-related pathways. After putting the gene status
into the significant pathways, we got three different types of alternatively-activated pathways. In most
previous gene set enrichment analysis methods [32,33], only the gene expression data were used.
To the best of our knowledge, our study is the first time that gene status information (PMA) was also
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used in pathway enrichment analysis. Compared to the gene expression data, the presence-absence
calls information was more suitable when we say the gene was active or inactive instead of the gene
expression value. For example, even genes that were not expressed generate signal values, usually
low; random fluctuations in these low values can often produce large apparent fold changes. A gene
also can be inactive even if the expression value was high when the background expression was also
high [67,68]. Batch effects were the systematic error introduced when samples were processed in
multiple batches. The batch effect is a common problem associated with microarray datasets and
cannot be eliminated unless the whole study is done in a single batch. In this research, there were
different platforms in the datasets, so PMA information instead of gene expression could reduce the
differences between platforms and help in dealing with batch effects.
Molecular networks under the primary cancer and metastasis conditions are complex dynamic
systems that demonstrate nonintuitive behaviors. Bayesian networks that infer probabilistic causal
relationships between network components based on gene expression are widely used in cancer
research [69,70]. Here, Bayesian networks constructed based on primary breast cancer and breast
cancer liver metastasis conditions separately were used to expand the pathways. Comparing the
condition-specific expanded pathways is more reasonable to understand the difference between them.
After mapping the genes with different activity status into significant pathways, we identified three
types of alternatively-activated pathways. Alternatively-activated pathways were widely researched
in cancer and metastasis [71]. However, this alternatively-activated pathway concept has not been
fully explored in the computational cancer system biology. This is the first time using microarray data
to identify alternatively-activated pathways in breast cancer liver metastasis.
In this study, we identified several metastasis-related pathways, such as the cytokine-cytokine
receptor interaction, calcium signaling, and TGF beta signaling pathways, and these pathways have
been proven to be related to breast cancer metastasis by previous research. Some cytokines (IL-1,
IL-6, IL-11, TGFβ) stimulate, while others (IL-12, IL-18, IFNs) inhibit breast cancer proliferation
and/or invasion [72]. In a few studies, multivariate analysis identified high serum IL-6 level as
an independent adverse prognostic variable for progression-free and overall survival in metastatic
breast cancer [73–75]. Calcium-activated chloride channel ANO1 was found to promote breast cancer
progression [76]. Deregulation of calcium homeostasis and signaling is associated with mammary
gland pathophysiology, and as such, calcium transporters, channels, and binding proteins represent
potential drug targets in breast cancer [77]. The role of TGF-beta in breast cancer progression is
ambiguous, as it was shown to display both tumor-suppressing and -promoting effects [78,79]. This is
consistent with our results, which it is significant in both primary cancer and metastasis.
Three types of alternatively-activated pathways were identified in our research: active states
of some gene-gene pairs were inversed; some sub-pathways were only active in primary cancer, or
metastatic cancer; and some sub-pathways were alternatively-activated by different genes. In the TGF-β
signaling pathway, E2F5 status was reported to improve the diagnosis of the malignancy of breast
tumors [80], epithelial ovarian cancer [81], and hepatocellular carcinoma [82]. Higher E2F4 activity
is predictive of worse survival [83]. In our study, we identified two different alternatively-activated
TGF-β signaling pathways, and the E2F5-related sub-pathway is related to breast cancer, while the
E2F4 related one is a risk for metastasis and potential worse survival. These results demonstrated the
effectiveness of our alternatively-activated pathway methods and results.
5. Conclusions
Overall, in this study, we proposed an alternatively-activated pathway mining method based on
microarray data and identified three types of alternatively-activated pathways between primary breast
cancer and breast liver metastatic cancer. The results showed that our proposed method was valid
and effective. In conclusion, our method may contribute to future mechanism study of breast cancer
metastasis and eventually to the development of therapeutic drugs that may prevent cancer metastasis.
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676 REACTOME pathways were downloaded from MsigDB v6.0 [34].
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